Henrich 2008 (T).

Methods	Participants were "randomised" and a "closed envelope extracted from a box after gaining consent". No other details available.
Participants	224 women with singleton pregnancies at over 37 weeks. Women with BS of 7 or more were excluded.
Interventions	Misoprostol‐group took at first 25μg orally, then 50μg, and on a third administration, 100 μg, each at a time, in a time span of four hours, up to a maximal dose of 175 μg the first day, and one of 300 μg in the second and third days. Minprostin‐group took each 6th hour 3 mg of Dinoprostone as vaginal tablets
Outcomes	Labour and delivery outcomes. Neonatal outcomes. Maternal side‐effect outcomes.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Insufficient information about the sequence generation process to permit judgement of ‘Low risk’ or ‘High risk’.
Allocation concealment (selection bias)	Low risk	A ‐ closed envelope.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Insufficient information to permit judgement of ‘Low risk’ or ‘High risk’
Selective reporting (reporting bias)	Unclear risk	Insufficient information to permit judgement of ‘Low risk’ or ‘High risk’.
Other bias	Unclear risk	Insufficient information to assess whether an important risk of bias exists.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Insufficient information to permit judgement of ‘Low risk’ or ‘High risk’.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information to permit judgement of ‘Low risk’ or ‘High risk’.